Information Provided By:
Fly News Breaks for November 7, 2019
Nov 7, 2019 | 10:16 EDT
Piper Jaffray analyst Tyler Van Buren believes "positive" Process B Fanconi anemia data and positive initial Phase I LAD-1 data by year-end will boost shares of Rocket Pharmaceuticals higher. Sales from Rocket's lentiviral pipeline alone could exceed $1B, while the Danon's disease program has blockbuster potential of $3B or more, Van Buren tells investors in a research note. He keeps an Overweight rating on Rocket Pharmaceuticals with a $35 price target following the company's Q3 results.